Catheter Ablation for Atrial Fibrillation After Percutaneous Mitral Valve Repair

Catheter Ablation versus Medical treatment in Patients with Mitral Regurgitation who implanted percutaneous mitral valve repair and Atrial Fibrillation - CAMP-MRAF TRIAL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs042200051

Enrollment

Registered

2020-10-19

Start date

2020-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation Heart Failure, Mitral Regurgitation, Percutaneous Mitral Valve Repair, Atrial Fibrillation

Interventions

arm Catheter Ablation: cryoballoon ablation for atrial fibrillation. arm Drug: Drugs for atrial fbirillation will be continued.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients undergoing percutaneous mitral valve repair (PMVR) for mitral regurgitation 2)Patients with paroxysmal or persistent atrial fibrillation. Diagnosis of atrial fibrillation is performed with a 12-lead electrocardiogram, a Holter electrocardiogram, an implantable device (ICD / CRT-D / loop recorder), or a portable electrocardiograph. Case registration is limited to cases where atrial fibrillation has been recorded within one year retroactively from study registration. 3)Age at the time of PMVR treatment is 20 years old or older and less than 90 years old

Exclusion criteria

Exclusion criteria: 1)Patients undergoing percutaneous mitral valve repair (PMVR) for mitral regurgitation 2)Patients with paroxysmal atrial fibrillation (2 or more events lasting 30 seconds or more). Even if atrial fibrillation persists for 7 days or more, it is registered as paroxysmal atrial fibrillation when it becomes sinus rhythm by drug or cardioversion and then becomes paroxysmal atrial fibrillation. Diagnosis of atrial fibrillation is performed with a 12-lead electrocardiogram, a Holter electrocardiogram, an implantable device (ICD / CRT-D / loop recorder), or a portable electrocardiograph. Case registration is limited to cases where atrial fibrillation has been recorded within one year retroactively from study registration. 3)Age at the time of PMVR treatment is 20 years old or older and less than 90 years old

Design outcomes

Primary

Measure	Time frame
BNP, NT-proBNP	—

Secondary

Measure	Time frame
All-cause death, Heart failure hospitalization, stroke, major bleeding	—

Contacts

Public ContactNaoya Kataoka

Second department of internal medicine, University of Toyama

nkataoka@med.u-toyama.ac.jp+81-76-434-7297

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026